scholarly journals Transforming growth factor-beta signaling network regulates plasticity and lineage commitment of lung cancer cells

2014 ◽  
Vol 21 (8) ◽  
pp. 1218-1228 ◽  
Author(s):  
I Ischenko ◽  
J Liu ◽  
O Petrenko ◽  
M J Hayman
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Cancer Cells ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Signaling Network ◽  
Lung Cancer Cells ◽  
Lineage Commitment ◽  
Growth Factor Beta

Confluence-dependent resistance to cisplatin in lung cancer cells is regulated by transforming growth factor-beta

2016 ◽  
Vol 42 (4) ◽  
pp. 175-181 ◽  
Author(s):  
Saki Yokokura ◽  
Nobuhiro Kanaji ◽  
Akira Tadokoro ◽  
Shigeyuki Yokokura ◽  
Norimitsu Kadowaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Cancer Cells ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Lung Cancer Cells ◽  
Growth Factor Beta

scholarly journals Downregulation of NKG2DLs by TGF-β in human lung cancer cells

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Young Shin Lee ◽  
Hojung Choi ◽  
Hae-Ryung Cho ◽  
Woo-Chang Son ◽  
You-Soo Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Cells ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Nk Cell ◽  
Surface Proteins ◽  
Lung Cancer Cells ◽  
Human Lung Cancer ◽  
Altered Expression ◽  
Inhibitory Molecules

Abstract Background Transforming growth factor beta (TGF-β) is a typical immuno-inhibitory cytokine and highly secreted by lung cancer cells. It was supposed that its immunosuppressive effects to NK cell might be related with the altered expression of activating and inhibitory molecules in lung cancer cells. In this study, we examined the expression of NKG2DLs, PD-L1 and PD-L2 in lung cancer cells after treatment of TGF-β and a TGF-β inhibitor, Galunisertib (LY2157299). Results TGF-β reduced the level of surface proteins of five NKG2DLs without altered transcription levels in lung cancer cells. Galunisertib reversed the effect of TGF-β on the expression of NKG2DLs. Since MMP inhibitors, MMPi III and MMP2 inhibitor I, restored the reduced expression of NKG2DLs after treatment of TGF-β, it was thought that TGF-β induced the expression of MMP2 which facilitated the shedding of the NKG2DLs in cancer cells. However, the expression of PD-L1, L2 were not changed by treatment with TGF-β or Galunisertib. Conclusions Therefore, inhibition of TGF-β might reverse the immunosuppressive status on immune cells and restore NK cell mediated anticancer immune responses by upregulation of NKG2DLs in cancer cells.

Association between genetic variations in transforming growth factor beta pathway and overall survival in patients with non-small cell lung cancer treated with definitive radiotherapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e17530-e17530
Author(s):  
Weili Wang ◽  
Kerby A Shedden ◽  
Feng-Ming (Spring) Kong
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Definitive Radiotherapy ◽  
Growth Factor Beta ◽  
Tgfβ Pathway

e17530 Background: The transforming growth factor beta (TGFβ) pathway, an important regulator in cellular metabolic process, has been reported for significant association with cancer prognosis. This study was to exam the association between single nucleotide polymorphisms (SNPs) of TGFβ pathway and overall survival (OS) in subjects with non-small cell lung cancer (NSCLC). Methods: Patients with stage I-III NSCLC received definitive radiotherapy with/without chemotherapy were eligible to this prospective study. The primary endpoint was OS which was calculated from radiation treatment start to death or censored. DNA samples for genotyping were extracted from buffy-coat which was collected before commencement of treatment. 19 SNPs in 10 genes (BMP1, BMP2, INHBC, SMAD1, SMAD3, SMAD4, SMAD6, SMAD7, SMAD8, TGFβ1), which was reported to have significant correlation with OS of lung cancer, were selected. MassArray System (Sequenom Company) was used for genotyping. Cox regression was performed for multivariate analysis to examine the effects of genotypes on OS using dominant and recessive genetic model. Results: 126 consecutive patients, 91% of them were Caucasian, were recruited in this study. All SNPs call rates were over 90%. Assay reproducibility was over 99% by random double-blinding duplicate or triplicate genotyping. Among clinical factors analyzed, radiation dose was only significant independent factor predicting OS (P=0.001). Genotypic association study showed that 7 SNPs (rs235756, rs11939979, rs12102171, rs6494633, rs12456284, rs12906898 and rs4803455) were significantly associated with OS, adjusted for age, gender, smoking, histology, clinical stage, tumor volume, Karnofsky Performance Status, radiotherapy dose, and chemotherapy. The strongest association was in SMAD3: rs12102171 (P=0.004, HR=2.28, 95%CI, 1.26-4.15). Conclusions: This study partly validated findings from previous studies that genetic variations in the TGFβ pathway are significant predictors of overall survival in NSCLC patients treated with definitive radiotherapy with/without chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document